This meta-analysis provides compelling evidence that bariatric metabolic surgery (BMS) offers superior cardiovascular protection compared to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with obesity. The gene discussed is GLP1R; the disease is obesity disorder.